INTRODUCTION: Based upon evidence suggesting that concentrations of anti-heat shock protein-60 (anti-HSP60) and interleukin-2 (IL-2) are associated with atherogenesis, we tested the hypothesis that anti-HSP60 and IL-2 are associated with coronary artery calcium (CAC) score, a marker of subclinical atherosclerosis. METHODS: We evaluated 998 asymptomatic adults, age 45-84 years, without known coronary disease from the Multi-Ethnic Study of Atherosclerosis (MESA), who had anti-HSP60 measured at baseline. Tertiles of serum anti-HSP60 were evaluated. The associations of IL-2 and anti-HSP60 with CAC were assessed using multivariate analyses, with adjustments for coronary risk factors and Framingham risk score. RESULTS: Patients' demographics, diabetes, hypertension, obesity, or dyslipidaemia did not show differences in levels of anti-HSP60. The median (IQR) Framingham risk score was 11 (5-22), 8 (5-16), and 9 (5-18) for the first, second, and third tertiles, respectively (p=0.043). IL-2 and tumour necrosis factor α (TNF-α) were associated with increased CAC (IL-2: OR 3.70, p<0.001; TNF-α: OR 4.63, p<0.001). In multivariate regression, the highest tertiles of anti-HSP60 and IL-2 were associated with increased risk of CAC (HSP60 T3: OR 1.49, p=0.022; IL-2: OR 2.49, p<0.001). After adjustment, significant progression of CAC was observed in patients with higher baseline levels of anti-HSP60 (estimate 31.73, p=0.016) and IL-2 (estimate 34.39, p=0.024). CONCLUSIONS: Increased concentrations of inflammatory markers (IL-2 and anti-HSP60) are associated with an increased CAC at baseline and follow-up in healthy asymptomatic adults. Future studies should be carried out to assess its association with early development of atherosclerosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
INTRODUCTION: Based upon evidence suggesting that concentrations of anti-heat shock protein-60 (anti-HSP60) and interleukin-2 (IL-2) are associated with atherogenesis, we tested the hypothesis that anti-HSP60 and IL-2 are associated with coronary arterycalcium (CAC) score, a marker of subclinical atherosclerosis. METHODS: We evaluated 998 asymptomatic adults, age 45-84 years, without known coronary disease from the Multi-Ethnic Study of Atherosclerosis (MESA), who had anti-HSP60 measured at baseline. Tertiles of serum anti-HSP60 were evaluated. The associations of IL-2 and anti-HSP60 with CAC were assessed using multivariate analyses, with adjustments for coronary risk factors and Framingham risk score. RESULTS:Patients' demographics, diabetes, hypertension, obesity, or dyslipidaemia did not show differences in levels of anti-HSP60. The median (IQR) Framingham risk score was 11 (5-22), 8 (5-16), and 9 (5-18) for the first, second, and third tertiles, respectively (p=0.043). IL-2 and tumour necrosis factor α (TNF-α) were associated with increased CAC (IL-2: OR 3.70, p<0.001; TNF-α: OR 4.63, p<0.001). In multivariate regression, the highest tertiles of anti-HSP60 and IL-2 were associated with increased risk of CAC (HSP60 T3: OR 1.49, p=0.022; IL-2: OR 2.49, p<0.001). After adjustment, significant progression of CAC was observed in patients with higher baseline levels of anti-HSP60 (estimate 31.73, p=0.016) and IL-2 (estimate 34.39, p=0.024). CONCLUSIONS: Increased concentrations of inflammatory markers (IL-2 and anti-HSP60) are associated with an increased CAC at baseline and follow-up in healthy asymptomatic adults. Future studies should be carried out to assess its association with early development of atherosclerosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Mahmoud Al Rifai; Andrew P DeFilippis; John W McEvoy; Michael E Hall; Ana Navas Acien; Miranda R Jones; Rachel Keith; Hoda S Magid; Carlos J Rodriguez; Graham R Barr; Emelia J Benjamin; Rose Marie Robertson; Aruni Bhatnagar; Michael J Blaha Journal: Atherosclerosis Date: 2017-01-19 Impact factor: 5.162
Authors: Abhishek Maan; Neal W Jorgensen; Moussa Mansour; Samuel Dudley; Nancy S Jenny; Christopher Defilippi; Moyses Szklo; Alvaro Alonso; Marwan M Refaat; Jeremy Ruskin; Susan R Heckbert; E Kevin Heist Journal: Pacing Clin Electrophysiol Date: 2016-12-02 Impact factor: 1.976
Authors: Kwok Leung Ong; Robyn L McClelland; Matthew A Allison; Mary Cushman; Parveen K Garg; Michael Y Tsai; Kerry-Anne Rye; Fatiha Tabet Journal: Metabolism Date: 2021-01-07 Impact factor: 8.694
Authors: Jonas Bernardes de Lima Filho; Letícia Freire; Eliana Aguiar Petri Nahas; Fábio Lera Orsatti; Claudio Lera Orsatti Journal: Front Mol Biosci Date: 2020-06-12
Authors: Indumathi Krishnan-Sivadoss; Iván A Mijares-Rojas; Ramiro A Villarreal-Leal; Guillermo Torre-Amione; Anne A Knowlton; C Enrique Guerrero-Beltrán Journal: Med Res Rev Date: 2020-08-17 Impact factor: 12.388
Authors: Edward J Carr; James Dooley; Michelle A Linterman; Adrian Liston; Josselyn E Garcia-Perez; Vasiliki Lagou; James C Lee; Carine Wouters; Isabelle Meyts; An Goris; Guy Boeckxstaens Journal: Nat Immunol Date: 2016-02-15 Impact factor: 25.606